Intra- and extracellular magnesium levels and atheromatosis in haemodialysis patients

Magnesium Research

Volumn 17, Issue 2, 2004, Pages 102-108

  Tzanakis, Ioannis ^a,c   Virvidakis, Kyriakos ^b   Tsomi, Aggeliki ^b   Mantakas, Emmanouel ^a   Girousis, Nikolaos ^a   Karefyllakis, Nektarios ^a   Papadaki, Antonia ^a   Kallivretakis, Nikolaos ^a   Mountokalakis, Theodoros ^b  

^a General Hospital of Chania   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE   (Greece)

Author keywords

Atheromatosis; Haemodialysis; Intima media thickness; Magnesium

Indexed keywords

MAGNESIUM;

ADULT; AGED; ARTERY INTIMA; ARTERY MEDIA; ARTERY WALL; ARTICLE; ATHEROMATOSIS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CELL ISOLATION; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; HYPOMAGNESEMIA; KIDNEY FAILURE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHOSPHATE BLOOD LEVEL; ULTRASOUND;

ADULT; AGED; AGED, 80 AND OVER; ARTERIOSCLEROSIS; CAROTID ARTERY, COMMON; FEMALE; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 4243123000     PISSN: 09531424     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38: 26-9.
2. Durlach J, Durlach A, Durlach V. Commentary on recent epidemiological and clinical advances. Magnes Res 1996; 9: 139-41.
3. Agus MS, Agus ZS. Cardiovascular actions of magnesium. Crit Care Clin 2001; 17: 175-86.
4. Alturra BM, Altura BT. Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherogenesis. Cell Mol Biol Res 1995; 41: 347-59.
5. Gartside PS, Glueck CJ. The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalization and mortality: The prospective NHANES I follow-up study. J Am Coll Nutr 1995; 14: 71-9.
6. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities Study. Am Heart J 1998; 136: 480-90.
7. Meema HE, Oreopoulos DG, Rapaport A. Serum magnesium level and calcification in end - stage renal disease. Kidney Int 1987; 32: 388-94.
8. Tzanakis J, Pras A, Kounali D, Mamali V, Kartsonakis V, Mayopoulou - Symvoulidou D, Kallivretakis N. Mitral annular calcifications in hemodialysis patients: a possible protective role of magnesium. Nephrol Dial Transplant 1997; 12: 2036-7.
9. Kelepouris E, Agus ZS. Hypomagnesaemia: Renal magnesium Handling. Seméin Nephrol 1998; 18: 58-73.
10. Mountokalakis TD. Magnesium metabolism in chronic renal failure. Magnes Res 1990; 3: 121-7.
11. Simons PC, Algra A, Bots ML, Grobbee DE, Van Der Graaf Y. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second manifestation of ARTerial disease). Circulation 1999; 100: 951-7.
12. Daugirdas JT. Second generation logarithmic estimates of single pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-13.
13. Berglund GL. Introduction, Minisymposium: ultrasound in clinical trials of atherosclerosis. J Int Med 1994; 236: 551-3.
14. Naess A, Tonder O. Technical aspects of rosette tests for the demonstration of lymphocyte sub-populations. Acta Pathol Microbiol Immunol Scand [C] 1982; 90: 59-65.
15. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22.
16. Ahsan SK. Magnesium in health and disease. J Pak Med Assoc 1998; 48: 246-50.
17. Rayssiguier Y. Magnesium and lipid metabolism. In: Metal ions in biological systems, magnesium and its role in biology, nutrition and physiology, ed H. Singel, New York: Marcel Dekker, 1990, 341-358.
18. Schechter M, Sharir M, Labrador MJP, et al. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000; 102: 2353.
19. Sherer Y, Bitzur R, Cohen H, Shaish A, Varon D, Shoenfeld Y, Harats D. Mechanisms of action of the anti-atherogenic effect of magnesium: lessons from a mouse model. Magnes Res 2001; 14: 173-9.
20. Ravn HB, Korsholm TL, Falk E. Oral magnesium supplementation induces favorable antiatherogenic changes in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 858-62.
21. Ma J, Folsom AR, Melnick SL, et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol 1995; 48: 927-40.
22. Djurhuus MS, Skott P, Hother-Nielson O, Klitgaard NA, Beck-Nielsen H. Insulin increases renal magnesium excretion: a possible cause of magnesium depletion in hyperinsulinaemic states. Diabet Med 1995; 12: 664-9.
23. Altura BM, Altura BT, Gebrewold A. Magnesium deficiency and hypertension. Correlation between magnesium-deficient diets and microcirculatory changes. Science 1984; 223: 1315-7.
24. Foley RN, Parfrey PS, Harnett JD, et al. Hypoalbuminemia, cardiac morbidity and mortality in end stage renal disease. J Am Soc Nephrol 1996; 7: 728-36.
25. Salem M. Hypertension in the hemodialysis population? High time for answers. Am J Kidney Dis 1999; 33: 592-3.
26. Savage T, Clarke AL, Giles M, Tomson CRV, Raine AEG. Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease. Nephrol Dial Transplant 1998; 1: 2004-12.
27. Fleischmann EH, Bower JD, Salahuden AK. Are conventional risk factors predictive of two-years mortality in hemodialysis patients? Clin Nephrol 2001; 56: 211-20.